Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate To Consider User Fee Bill Soon, As Hopes For BCRA Passage With Device Tax Repeal Fade

Executive Summary

Sen. Lamar Alexander, R-Tenn., has placed the user fee FDA Reauthorization Act on the Senate legislative calendar, and is just waiting on a nod from the chamber leadership to bring it up for consideration on the floor. On July 18, after successfully passing an Agriculture/FDA funding bill for 2018 onto the full committee, Ag/FDA Subcommittee Chair John Hoeven, R-N.D., characterized FDARA as non-controversial and ripe for passage. Meanwhile, industries' hopes for device tax repeal as part of legislation repealing the Affordable Care Act are fading away.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel